Han Si
AstraZeneca
9 Papers
30 Citations
Han Si is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Tremelimumab. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang,Jia Luo,Song Wu,Han Si,Chen Gao,Wenjing Xu,Shaad Essa Abdullah,Brandon Higgs,Phillip A. Dennis,Michiel S. van der Heijden,Neil H. Segal,Jamie E. Chaft,Jamie E. Chaft,Todd Hembrough,J. Carl Barrett,Matthew D. Hellmann,Matthew D. Hellmann +16 more
TL;DR: A concept of "molecular response" using ctDNA is proposed, incorporating both pretreatment and on-treatment VAF that predicted long-term survival similarly to initial radiological response, while also permitting early differentiation of responders among patients with initially radiologically stable disease.
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si,M. Kuziora,Katie Quinn,Elena Helman,Jiabu Ye,F. Liu,U. Scheuring,Solange Peters,Naiyer A. Rizvi,Philip Z Brohawn,Koustubh Ranade,Brandon Higgs,Kimberly C. Banks,Vikram Chand,Rajiv Raja +14 more
TL;DR: In this article, the authors used the GuardantOMNI ctDNA platform for quantifying tumor mutational burden (TMB) in the blood of patients with non-small cell lung cancer.
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
Weimin Li,Sophie Wildsmith,Jiabu Ye,Han Si,Nassim Morsli,Philip He,J. Shetty,Alejandro Javier Yovine,Nicholas Holoweckyj,Rajiv Raja,Katia Real,Paul Scorer,Todd Hembrough,Jill Walker,Qu Zhang,Ricard Mesia,Robert I. Haddad,Lisa Licitra,Robert L. Ferris +18 more
TL;DR: It is shown that bTMB assessed from circulating tumor DNA shows promise as a predictive survival biomarker for immunotherapy, but its value in R/M HNSCC is uncertain.
30
A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.
Yelena Lazdun,Han Si,Todd Creasy,Koustubh Ranade,Brandon Higgs,Katie Streicher,Nicholas M. Durham +6 more
TL;DR: The development of a systematic approach to efficiently identify and validate immunogenic neoantigens that may help to identify patients who will survive longer on durvalumab is described.
8
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
Weimin Li,Athena Matakidou,Zara Ghazoui,Han Si,Sophie Wildsmith,Nassim Morsli,Helen Mann,Magdalena Wrona,Melissa de los Reyes,Rajiv Raja,Craig Barker,Jessica Whiteley,Qu Zhang,Jérôme Fayette,Dan P. Zandberg,Ricard Mesia,Lillian L. Siu +16 more
TL;DR: Baseline tumor and germline biomarkers in R/M HNSCC were analyzed for predictive potential in pts benefitting from D or D+T and showed positive results.
6